Lerivon (Mianserin Hydrochloride)

Mianserin hydrochloride blocks presynaptic alpha‑2 adrenergic receptors, which increases norepinephrine release. It also antagonizes histamine H1 and serotonin 5‑HT2 receptors, enhancing serotonergic and noradrenergic signaling that contributes to its antidepressant effect.

The appropriate dose of Lerivon is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy, and tolerability. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for Mianserin hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made in consultation with a qualified healthcare provider.

To order Lerivon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lerivon belongs to the tetracyclic antidepressant class, which differs from selective serotonin reuptake inhibitors (SSRIs) in its receptor profile. While SSRIs primarily inhibit serotonin reuptake, Mianserin also blocks alpha‑2 adrenergic and histamine receptors, offering a distinct side‑effect and efficacy profile that may be advantageous for certain patients.

Lerivon tablets should be stored at ambient temperature below 25 °C, in their original packaging, and protected from moisture and direct light. Keep the product out of reach of children and do not use after the expiry date.

Lerivon is taken orally, usually with or without food, as directed by a healthcare professional. The tablets should be swallowed whole with an adequate amount of water and not crushed or chewed unless specifically advised.

Serious risks include agranulocytosis, seizures, cardiac arrhythmias such as QT prolongation, severe hypotension, hepatic dysfunction, and the emergence or worsening of suicidal thoughts. Patients should be monitored closely for any of these events and seek immediate medical attention if they occur.

Lerivon is contraindicated in patients with known hypersensitivity to Mianserin hydrochloride or any excipients, those currently receiving monoamine oxidase inhibitors, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of cardiac conduction disorders or severe hypotension.